GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes

Key Findings

GLP-1 Users Are Drinking Less — and Saying So 🍺

• A nationally representative survey found that people who started GLP-1 drugs reported reducing their alcohol consumption after initiation, published in JAMA Psychiatry.
• A separate editorial synthesizing randomized trial data noted the strongest signals were in heavy-drinking days and drinks per drinking day — not total abstinence — and suggested the best candidates may be people who also have obesity or high cardiovascular risk.

Tirzepatide After a Price Hike: What 1 Million UK Users Did Next 💸

• After tirzepatide's UK list price rose by up to 170% in September 2025, treatment patterns shifted noticeably among self-paying users through a large telehealth provider — covering over one million adults with overweight or obesity.
• The study also estimated longitudinal weight trajectories, offering a rare real-world look at what happens to outcomes when cost suddenly changes who stays on treatment.

Muscle Loss on GLP-1 Drugs: Real Concern, Murky Evidence 💪

• A narrative review covering studies published primarily between 2016 and 2026 found that GLP-1-based drugs reduce fat mass more than lean mass — but lean mass is not the same as skeletal muscle, and direct measures of muscle function were assessed in only a small number of studies with mixed results.
• Preclinical data showed both potentially protective mechanisms and signs of muscle breakdown, leaving the net effect on sarcopenia risk genuinely unresolved.

Semaglutide Linked to Better Heart Failure Outcomes — When Doctors Actually Prescribe It

• A prospective clinical effectiveness study found that a nurse practitioner-led program using GLP-1 drugs improved symptoms and weight in patients with obesity-related heart failure with preserved ejection fraction — but the study also documented that uptake in routine cardiovascular practice remains inconsistent.
• The gap between clinical trial evidence and real-world prescribing is the finding: semaglutide has trial support for this condition, yet the drug isn't reliably reaching the patients most likely to benefit.

Gut Bacteria Metabolites May Slow GLP-1 Breakdown 🦠

• Lab experiments found that acetate, propionate, and butyrate — short-chain fatty acids produced by gut bacteria — inhibited the enzyme that rapidly degrades GLP-1, and preserved GLP-1-induced signaling in insulin-secreting cells.
• The inhibition was reversible and concentration-dependent, suggesting a potential molecular link between gut microbial activity and how long your body's own GLP-1 stays active — though this remains early-stage, in-vitro work.

GLP-1 Drugs for Neurodegeneration: The Hype Outruns the Data 🧬

• A narrative review of preclinical and clinical evidence found that while GLP-1 drugs modulate inflammation and insulin signaling relevant to neurodegeneration, liraglutide failed its primary endpoint in an Alzheimer's trial and semaglutide did not slow clinical progression.
• Parkinson's trials yielded mixed results, and observational associations with reduced dementia risk remain susceptible to confounding — the review concludes that greater metabolic efficacy does not establish neuroprotection.